Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Abnormalities, Drug-Induced Clear all
Completed Phase 2Phase 3 Interventional

Recovery Housing For Drug Dependent Pregnant Women

NCT00497302
View directory record Official record
Conditions
Drug Addiction
Interventions
RBT, usual care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 25, 2026, 7:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy

NCT03831113
View directory record Official record
Conditions
Opiate Addiction, Pregnancy
Interventions
Magnitude Group, Frequency Group
Drug
Lead sponsor
Steve N. Caritis, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

NCT00076323
View directory record Official record
Conditions
Glucosephosphate Dehydrogenase Deficiency, Favism
Interventions
Primaquine
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

NCT03576469
View directory record Official record
Conditions
CVI - Common Variable Immunodeficiency
Interventions
C1-esterase inhibitor [recombinant] (C1-INH-R)
Biological
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain

NCT03396588
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Morphine
Drug
Lead sponsor
Henrietta Bada
Other
Eligibility
12 Hours to 7 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

NCT00829829
View directory record Official record
Conditions
Intercritical Gout
Interventions
Placebo, Rilonacept 80 mg, Rilonacept 160 mg
Other · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
67
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 25, 2026, 7:33 PM EDT
Completed No phase listed Observational

Surgical Treatment of Children With OSA and Small Tonsils or Down Syndrome

NCT05154214
View directory record Official record
Conditions
Obstructive Sleep Apnea of Child
Interventions
Adenotonsillectomy, Drug-induced sleep endoscopy directed surgery
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

NCT02119091
View directory record Official record
Conditions
Cardiac Toxicity
Interventions
Moxifloxacin
Drug
Lead sponsor
Haiyan Li
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

NCT04675788
View directory record Official record
Conditions
Long QT Syndrome, Abnormalities, Drug-Induced
Interventions
Progesterone, Ibutilide, Testosterone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
50 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reducing the Risk of Drug-Induced QT Interval Lengthening in Women

NCT03834883
View directory record Official record
Conditions
Long QT Syndrome, Abnormalities, Drug-Induced
Interventions
Progesterone, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional

Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

NCT04330625
View directory record Official record
Conditions
Hyperglycemia Drug Induced
Interventions
REMD-477
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 25, 2026, 7:33 PM EDT
Active, not recruiting No phase listed Observational

ESIS in Pediatric DRE

NCT05469373
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Sarah Katie Ihnen
Other
Eligibility
1 Year to 30 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 25, 2026, 7:33 PM EDT
Terminated Phase 1 Interventional Results available

Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure

NCT00585546
View directory record Official record
Conditions
Heart Failure, Dilated Cardiomyopathy
Interventions
clenbuterol
Drug
Lead sponsor
Francis D. Pagani
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 2 Interventional Results available

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

NCT02819856
View directory record Official record
Conditions
Ototoxicity
Interventions
Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Recruiting Not applicable Interventional

The Oklahoma Parent-Child Assistance Program

NCT05534568
View directory record Official record
Conditions
Substance Use Disorders, Pregnancy Related, Alcohol Use Disorder (AUD), Alcohol Use Complicating Pregnancy, First Trimester, Alcohol Use Complicating Pregnancy, Second Trimester, Alcohol Use Complicating Pregnancy, Third Trimester, Alcohol Use Complicating Pregnancy, Unspecified Trimester, Alcohol Use Complicating Pregnancy, Childbirth, and the Puerperium, Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome, Drug Use Disorders, Drug Use Complicating Pregnancy, First Trimester, Drug Use Complicating Pregnancy, Second Trimester, Drug Use Complicating Pregnancy, Third Trimester, Drug Use Complicating Pregnancy, Unspecified Trimester, Drug Use Complicating Pregnancy, Childbirth, and the Puerperium, Maternal Drugs Affecting Fetus
Interventions
Parent-Child Assistance Program
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 3 Interventional Results available

Medication Treatment for Opioid Use Disorder in Expectant Mothers

NCT03918850
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 1 Interventional

A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir

NCT00000970
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 7:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers

NCT00001771
View directory record Official record
Conditions
Healthy, Mental Disorder, Obsessive Compulsive Disorder, Schizophrenia, Tourette Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 25, 2026, 7:33 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hyaluronidase Via LADD Scleroderma-induced Microstomia

NCT05995626
View directory record Official record
Conditions
Microstomia, Scleroderma
Interventions
Hyaluronidase, CO2 laser
Drug · Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 25, 2026, 7:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Qualitative Understanding of Experiences With the SIMPLIFY Trial

NCT04320381
View directory record Official record
Conditions
Cystic Fibrosis, Drug Withdrawal
Interventions
Qualitative Interview
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
14 Years and older
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 25, 2026, 7:33 PM EDT